Our team has deep expertise in neuroscience and drug development and is committed to unlocking the potential of those living with debilitating diagnoses.


A Sanskrit word, karuna is an action taken to alleviate the suffering of others.

We’re taking action to deliver a more effective therapeutic option to the 21 million people worldwide affected by schizophrenia, as well as targeting Alzheimer’s and pain.


karuna is developing novel therapies for psychiatric and neurological disorders. our lead product candidate, Karxt, selectively activates muscarinic acetylcholine receptors in the brain and unlocks the therapeutic potential of xanomeline which previously demonstrated significant benefits in phase 2 studies in schizophrenia and alzheimer’s.